{
  "patient_id": "linda_k",
  "extraction_metadata": {
    "extracted_from": ["01_Prior_Auth_Request_Form.pdf", "02_Laboratory_Results.pdf", "03_Imaging_Report.pdf"],
    "extraction_date": "2026-02-07",
    "extraction_method": "clinical_document_extraction"
  },

  "demographics": {
    "first_name": "Linda",
    "last_name": "Kowalski",
    "date_of_birth": "1968-04-12",
    "age": 57,
    "gender": "Female",
    "ethnicity": "Polish American",
    "address": { "street": "4521 North Oakland Avenue", "city": "Milwaukee", "state": "WI", "zip": "53211" },
    "phone": "414-555-0167",
    "mrn": "LINDA_K",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "insurance": {
    "primary": {
      "payer_name": "Humana",
      "payer_id": "HUMANA",
      "plan_name": "Humana Gold Plus HMO",
      "plan_type": "HMO",
      "member_id": "HUM345678912",
      "group_number": "WI-HMO-2024",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  },

  "prescriber": {
    "name": "Dr. Elizabeth Murray",
    "credentials": "MD, FACR",
    "npi": "1789123456",
    "specialty": "Rheumatology",
    "practice_name": "Medical College of Wisconsin Rheumatology",
    "address": { "street": "9200 W Wisconsin Avenue", "city": "Milwaukee", "state": "WI", "zip": "53226" },
    "phone": "414-555-0600",
    "fax": "414-555-0601",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "medication_request": {
    "medication_name": "Infliximab",
    "brand_name": "Inflectra",
    "generic_name": "infliximab-dyyb",
    "j_code": "Q5103",
    "product_type": "preferred_biosimilar",
    "dose": "5mg/kg",
    "route": "Intravenous infusion",
    "frequency": { "induction": "Weeks 0, 2, 6", "maintenance": "Every 8 weeks" },
    "duration_requested": "12 months initial authorization",
    "quantity_requested": "4 infusions",
    "site_of_care": "Outpatient infusion center",
    "start_date_requested": "2026-02-28",
    "diagnosis": "Psoriatic arthritis",
    "icd10_code": "L40.50",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "diagnoses": [
    {
      "rank": "primary",
      "icd10_code": "L40.50",
      "description": "Arthropathic psoriasis, unspecified",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "rank": "secondary",
      "icd10_code": "L40.0",
      "description": "Psoriasis vulgaris",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "disease_activity": {
    "assessment_date": "2026-01-18",
    "swollen_joint_count": 8,
    "tender_joint_count": 14,
    "dactylitis_present": true,
    "dactylitis_digits": ["left 2nd toe", "right 3rd finger"],
    "enthesitis_present": true,
    "enthesitis_sites": ["bilateral Achilles", "bilateral plantar fascia"],
    "bsa_psoriasis": 18,
    "pasi_score": 14.2,
    "disease_severity": "moderate_to_severe",
    "nail_involvement": true,
    "source_documents": ["01_Prior_Auth_Request_Form.pdf"]
  },

  "clinical_history": {
    "chief_complaint": "Progressive joint pain and swelling with worsening skin psoriasis, dactylitis, and enthesitis despite methotrexate",
    "history_of_present_illness": "57-year-old female with psoriatic arthritis diagnosed 2019, with concurrent plaque psoriasis (BSA 18%, PASI 14.2). 8 swollen and 14 tender joints, active dactylitis in 2 digits, bilateral Achilles enthesitis. Nail psoriasis in 8/10 fingernails. Failed methotrexate (25mg SQ weekly for 6 months, inadequate response for both skin and joints) and leflunomide (elevated LFTs requiring discontinuation). Current functional limitations include difficulty with grip strength, walking >1 block, and climbing stairs.",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "prior_treatments": [
    {
      "medication_name": "Methotrexate",
      "drug_class": "csDMARD",
      "dose": "25mg SQ weekly",
      "start_date": "2024-04-01",
      "end_date": "2025-04-01",
      "duration_weeks": 52,
      "outcome": "inadequate_response",
      "outcome_description": "Inadequate response for both articular and cutaneous disease at maximum dose for 12 months. Persistent polyarthritis with PASI >12.",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Leflunomide",
      "brand_name": "Arava",
      "drug_class": "csDMARD",
      "dose": "20mg daily",
      "start_date": "2025-05-01",
      "end_date": "2025-08-15",
      "duration_weeks": 15,
      "outcome": "intolerance",
      "outcome_description": "Elevated hepatic transaminases (ALT 3.5x ULN) requiring discontinuation",
      "adverse_event": { "type": "hepatotoxicity", "details": "ALT 3.5x ULN", "severity": "moderate" },
      "adequate_trial": false,
      "reason_inadequate": "discontinued_due_to_adverse_event",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Apremilast",
      "brand_name": "Otezla",
      "drug_class": "PDE4 inhibitor",
      "dose": "30mg BID",
      "start_date": "2025-09-01",
      "end_date": "2025-12-15",
      "duration_weeks": 15,
      "outcome": "inadequate_response",
      "outcome_description": "Minimal improvement in joint symptoms. PASI improved only marginally (from 16 to 14.2). Persistent enthesitis and dactylitis.",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "laboratory_results": {
    "collection_date": "2026-01-15",
    "ordering_provider": "Dr. Elizabeth Murray",
    "facility": "MCW Clinical Lab",
    "report_status": "FINAL",
    "source_document": "02_Laboratory_Results.pdf",
    "panels": {
      "cbc": {
        "panel_name": "Complete Blood Count (CBC)",
        "results": [
          {"test": "WBC", "value": 8.2, "unit": "x10^9/L", "reference_range": "4.5-11.0", "flag": null},
          {"test": "Hemoglobin", "value": 12.5, "unit": "g/dL", "reference_range": "12.0-16.0", "flag": null},
          {"test": "Platelets", "value": 295, "unit": "x10^9/L", "reference_range": "150-400", "flag": null}
        ]
      },
      "inflammatory_markers": {
        "panel_name": "Inflammatory Markers",
        "results": [
          {"test": "CRP", "value": 15, "unit": "mg/L", "reference_range": "0-5", "flag": "H"},
          {"test": "ESR", "value": 28, "unit": "mm/hr", "reference_range": "0-20", "flag": "H"}
        ]
      },
      "hepatic_panel": {
        "panel_name": "Hepatic Panel",
        "results": [
          {"test": "ALT", "value": 32, "unit": "U/L", "reference_range": "7-56", "flag": null},
          {"test": "AST", "value": 28, "unit": "U/L", "reference_range": "10-40", "flag": null}
        ]
      }
    },
    "interpretation": "Moderately elevated CRP (15) and ESR (28) consistent with active inflammatory arthritis. LFTs normalized after leflunomide washout. CBC normal."
  },

  "pre_biologic_screening": {
    "status": "COMPLETE",
    "tuberculosis_screening": { "status": "COMPLETE", "test_performed": "QuantiFERON-TB Gold Plus", "result": "Negative", "cleared_for_biologic": true },
    "hepatitis_b_screening": { "status": "COMPLETE", "interpretation": "HBV negative with immunity from vaccination", "cleared_for_biologic": true },
    "hepatitis_c_screening": { "status": "COMPLETE", "result": "Non-reactive", "cleared_for_biologic": true }
  },

  "pa_criteria_assessment": {
    "diagnosis_confirmed": { "met": true, "evidence": "PsA confirmed with polyarthritis, dactylitis, enthesitis, and concurrent plaque psoriasis (PASI 14.2)" },
    "disease_severity_documented": { "met": true, "evidence": "8 swollen/14 tender joints, active dactylitis, enthesitis, BSA 18%, PASI 14.2" },
    "conventional_therapy_failed": {
      "met": true,
      "therapies_tried": [
        {"medication": "Methotrexate", "outcome": "inadequate_response", "duration_adequate": true},
        {"medication": "Leflunomide", "outcome": "intolerance", "duration_adequate": false},
        {"medication": "Apremilast", "outcome": "inadequate_response", "duration_adequate": true}
      ]
    },
    "step_therapy_satisfied": { "met": true },
    "pre_biologic_screening_complete": { "met": true },
    "fda_approved_indication": { "met": true, "indication": "Active psoriatic arthritis" }
  },

  "overall_pa_readiness": {
    "status": "READY_FOR_SUBMISSION",
    "all_clinical_criteria_met": true,
    "recommendation": "All criteria met. Multi-domain PsA (polyarthritis, dactylitis, enthesitis, skin) with failure of 3 conventional agents. Submit immediately."
  }
}
